A Study of HQP1351 in Patients With GIST or Other Solid Tumors
A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Oral HQP1351 in Patients With GIST or Other Solid Tumors.
Sponsor: Ascentage Pharma Group Inc.
Listed as NCT03594422, this PHASE1 trial focuses on Gastrointestinal Stromal Tumor (GIST) and Solid Tumor, Adult and remains actively recruiting participants. Sponsored by Ascentage Pharma Group Inc., it has been updated 17 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
17 versions recorded-
Mar 2025 — Present [monthly]
Recruiting PHASE1
-
Sep 2024 — Mar 2025 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
Nov 2023 — Apr 2024 [monthly]
Recruiting PHASE1
▶ Show 12 earlier versions
-
Mar 2023 — Nov 2023 [monthly]
Recruiting PHASE1
-
Sep 2022 — Mar 2023 [monthly]
Recruiting PHASE1
-
Feb 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
Jun 2021 — Feb 2022 [monthly]
Recruiting PHASE1
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Nov 2019 — Dec 2020 [monthly]
Recruiting PHASE1
Status: Completed → Recruiting
-
Oct 2019 — Nov 2019 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Aug 2019 — Oct 2019 [monthly]
Recruiting PHASE1
-
Dec 2018 — Aug 2019 [monthly]
Recruiting PHASE1
-
Sep 2018 — Dec 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Aug 2018 — Sep 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Jul 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ascentage Pharma Group Inc.
- HealthQuest Pharma Inc.
For direct contact, visit the study record on ClinicalTrials.gov .